Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Safran

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
Cell Death Discovery|August 18, 2020
Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killingIlyas Sahin, Shengliang Zhang, Arunasalam Navaraj, et al.
Cell Death Discovery|July 14, 2020
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killingIlyas Sahin, Shengliang Zhang, Arunasalam Navaraj, et al.
Oncogene|January 28, 2024
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)Matthew J Hadfield, Howard Safran, Marco A Purbhoo, et al.
Advances in Hematology|February 8, 2012
Nonengraftment haploidentical cellular therapy for hematologic malignanciesJohn L Reagan, Loren D Fast, Eric S Winer, et al.
Plos One|February 25, 2017
Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot studyAndrew Schumacher, William M Sikov, Matthew I Quesenberry, et al.
Frontiers in Oncology|October 12, 2012
Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung CancerJaroslaw T Hepel, Justin Peter, Jessica R Hiatt, et al.
Pancreas|July 20, 2002
Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinomaKevin S Palumbo, Jack R Wands, Howard Safran, et al.
Neoplasia (New York, N.Y.)|July 10, 2021
EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPGYiqun Zhang, Lanlan Zhou, Howard Safran, et al.
Rhode Island Medical Journal (2013)|February 25, 2026
Cancer Screening and Barriers to Screening Among Unhoused Individuals in Rhode IslandBoris Martinez, Pamela Jennings, Matt Strik, et al.
Human Pathology|July 2, 2017
Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinomaEvgeny Yakirevich, Shaolei Lu, Danisha Allen, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
Cell Death Discovery|August 18, 2020
Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killingIlyas Sahin, Shengliang Zhang, Arunasalam Navaraj, et al.
Cell Death Discovery|July 14, 2020
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killingIlyas Sahin, Shengliang Zhang, Arunasalam Navaraj, et al.
Oncogene|January 28, 2024
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)Matthew J Hadfield, Howard Safran, Marco A Purbhoo, et al.
Advances in Hematology|February 8, 2012
Nonengraftment haploidentical cellular therapy for hematologic malignanciesJohn L Reagan, Loren D Fast, Eric S Winer, et al.
Plos One|February 25, 2017
Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot studyAndrew Schumacher, William M Sikov, Matthew I Quesenberry, et al.
Frontiers in Oncology|October 12, 2012
Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung CancerJaroslaw T Hepel, Justin Peter, Jessica R Hiatt, et al.
Pancreas|July 20, 2002
Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinomaKevin S Palumbo, Jack R Wands, Howard Safran, et al.
Neoplasia (New York, N.Y.)|July 10, 2021
EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPGYiqun Zhang, Lanlan Zhou, Howard Safran, et al.
Rhode Island Medical Journal (2013)|February 25, 2026
Cancer Screening and Barriers to Screening Among Unhoused Individuals in Rhode IslandBoris Martinez, Pamela Jennings, Matt Strik, et al.
Human Pathology|July 2, 2017
Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinomaEvgeny Yakirevich, Shaolei Lu, Danisha Allen, et al.
Pageof 12